Vitamin D Supplements Could Reduce Multiple Sclerosis Symptoms, Study Suggests

Vitamin D deficiency has long been linked to an increased risk of multiple sclerosis (MS), but now a new study suggests that high doses of vitamin D supplementation might actually help reduce symptoms of the disease. This breakthrough could open new doors for early-stage MS treatment.

The study, conducted in France, involved 303 adults who had recently experienced clinically isolated syndrome (CIS) — an initial period of neurological symptoms that may precede MS. One group received high doses of cholecalciferol (vitamin D3) — 100,000 IU every two weeks — while another group was given a placebo for 24 months.

Results showed that 60.3% of the vitamin D group experienced either a relapse of symptoms or new or enlarged lesions, compared to 74.1% in the placebo group. A "statistically significant difference," researchers from CHU Nîmes, Université Montpellier, and multiple sclerosis centers in France noted. The findings were published in the journal JAMA, sparking interest across the medical community.

Researcher commentary emphasized the need for further studies, particularly regarding the role of high-dose vitamin D as an add-on therapy. Bruce Bebo, executive vice president of research at the National MS Society, weighed in, calling the study "well-designed." Bebo acknowledged that earlier studies using lower doses had failed to demonstrate similar benefits but noted that high doses might be effective in early-stage MS patients who are vitamin D deficient.

The American Academy of Neurology currently recommends daily doses of 300 to 4,000 IU for adults — far below the 100,000 IU used in this study. While no adverse effects were reported, Bebo warned that excessive vitamin D intake could lead to toxicity, causing symptoms like nausea, vomiting, frequent urination, and, in extreme cases, kidney damage. This is a reminder that even "miracle cures" need balance and caution.

For those with MS considering vitamin D supplements, consultation with a neurologist or primary care provider remains crucial to determining the safest and most effective approach.